Skip to content

Diagnostic Properties of Aldosterone-Renin Ratio in Primary Aldosteronism Among Hypertensives.

Aldosterone-Renin Ratio to Diagnose Primary Aldosteronism in a Population of Patients With Therapy-Resistant Hypertension: Test Characteristics, Diagnostic Value and Predictive Value for Antihypertensive Treatment. The Dutch ARRAT Study.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00407784
Enrollment
500
Registered
2006-12-05
Start date
2007-01-31
Completion date
2009-11-30
Last updated
2007-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperaldosteronism, Hypertension

Keywords

primary aldosteronism, hypertension, aldosteron-renin ratio, eplerenone, aldosteron-receptor antagonist, screening

Brief summary

This study aims to evaluate the diagnostic value of the Aldosterone-Renin Ratio (ARR)as a screening test for primary aldosteronism among hypertensives. The test characteristics will be studied. Furthermore, the effect of eplerenone, a selective aldosterone-receptor antagonist will be studied.

Detailed description

Although primary aldosteronism (PA) was formerly seen as a rare cause of hypertension, this condition is now thought to be the commonest cause of secondary hypertension, with the prevalence ranging up to 10-15 % of all hypertensives. Identification of patients with PA allows for specific treatment, for instance unilateral adrenalectomy in case of an aldosterone-producing adenoma or the administration of an aldosterone-receptor antagonist in case of bilateral adrenal hyperplasia. Since the introduction of the aldosterone-renin ratio (ARR) as a screening tool for PA in 1981, there has been considerable debate about the diagnostic value. The values for aldosterone and renin are highly dependent on many factors, including posture, time of day and medication. Also, the cut-off values for the identification of PA remain controversial. This study aims to evaluate the test characteristics of the ARR in a population of patients with therapy-resistant hypertension, the dependence of the ARR on medication type and the predictive value on the response on eplerenone, a selective aldosterone-receptor antagonist.

Interventions

DRUGeplerenone

Sponsors

Dutch Kidney Foundation
CollaboratorOTHER
Pfizer
CollaboratorINDUSTRY
Erasmus Medical Center
Lead SponsorOTHER

Study design

Observational model
DEFINED_POPULATION
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* age 18-65 years * blood pressure above 140 mmHg systolic and above 90 mmHg diastolic * use of at least 2 antihypertensive drugs

Exclusion criteria

* known cause of hypertension, including white-coat hypertension * severe renal failure (kreat \> 200 umol/l) * BMI above 32 kg/m2 * poorly regulated diabetes mellitus (HbA1C \> 8.0 %) * heart failure * stroke or myocardial infarction within 6 months before inclusion * angina pectoris * pregnancy * neoplastic disease, within 5 years before inclusion * alcohol abuse

Countries

Netherlands

Contacts

Primary ContactPieter Jansen, MD
p.jansen.1@erasmusmc.nl+31(0)-4632196
Backup ContactA.H. van den Meiracker, MD, PhD
a.vandenmeiracker@erasmusmc.nl+31(0)-4634220

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026